С	ase 8:10-cv-01873-AG -	MLG	Document 88	Filed 01/18/11	Page 1 of 5	Page ID #:1259
1	J. Thomas Greene (Ca	al. Bar	No. 57159)			
2	tgreene2@ftc.gov Federal Trade Commi	ission				
3	600 Pennsylvania Ave Washington, DC 2058 Tel: (202) 326-2531	e., NW 30	Ţ			
4	Tel: (202) 326-2531 Fax: (202) 326-2624					
5	Stephen A. Mohr (Cal smohr@ftc.gov	l. Bar	No. 246340)			
6	Federal Trade Commi 600 Pennsylvania Ave	ission	V			
7	Washington, DC 2058 Tel: (202) 326-2850	30	•••			
8	Fax: (202) 326-2624					
9	Counsels for Plaintiff					
10						
11 12						
12	IN THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA SOUTHERN DIVISION					
13						
15						
16	FEDERAL TRADE C		)			
17		PI	aintiff, )	No SACV 1	0 1972 AC	
18	v. LABORATORY CORPORATION O AMERICA, et al,			<ul> <li>No. SACV-10-1873-AG (MLGx)</li> <li>PLAINTIFF FEDERAL TRADE</li> </ul>		
19			ATION OF )	COMMISSI	ION'S OPPO	
20		D	efendant.	CLINICAL	LABORAT OR AN	ORIES'
21			}	ADDITION PROTECTI	AL BROAD VE ORDER	
22			}	Date: Januar	y 28, 2011	
23			}	Judge: Hon.	Andrew J. G	uilford
24 25	Plaintiff Federal Trade Commission (the "Commission") respectfully requests that the Court deny nonparty Sun Clinical Laboratories' ("Sun") Motion for an Additional Broader Protective Order. Sun has asked this court to prohibit					
25 26						
20 27						
28			1			
			1			

the Federal Trade Commission from "disclos[ing], disseminat[ing], release[ing], exchang[ing] to or with any party in this proceeding or us[ing], referenc[ing], quot[ing], or lodg[ing] as evidence for any purpose" the materials Sun provided to the FTC during its investigation of Defendants' Laboratory Corporation of America and Laboratory Corporation of America Holdings (collectively, "LabCorp") purchase of Westcliff Medical Laboratories, Inc ("Westcliff"). This Court entered a Protective Order Governing Confidential Material ("Protective Order") on January 4, 2010 that prevents the disclosure of Sun's confidential or proprietary information to anyone beyond LabCorp's outside counsel, thus protecting the interests that Sun has identified in its Motion. The materials at issue are an important component of the record, which will be less complete without their inclusion, particularly with respect to market share calculations for LabCorp and Westcliff, which will be inaccurate if the parties are unable to rely on the market share data submitted by Sun. Therefore, this Court should deny Sun's Motion.

## **ARGUMENT**

The provisions in the Protective Order are consistent with the standard provisions used in litigation before the FTC. *See* 16 C.F.R. § 3.31, Appendix A. Pursuant to the Protective Order, all the material that Sun desires to protect will be designated "Highly Confidential – Outside Counsel Only" and may only be disclosed to LabCorp's outside counsel. Protective Order ¶¶ 1, 2, 3, 7. Outside counsel may only use this information "for the purposes of the preparation and hearing of this proceeding, or any appeal therefrom, or for the purpose of the preparation and hearing in the FTC administrative proceeding directly related to this proceeding, and for no other purpose whatsoever." *Id.* ¶ 11. Based on these provisions, LabCorp cannot use Sun's documents or information to gain any

competitive advantage over Sun and therefore Sun's concerns about LabCorp's 1 potential misuse of Sun's information are unfounded.<sup>1</sup> 2

It is critical that the FTC be permitted to rely on and lodge into evidence the 3 information submitted by Sun.<sup>2</sup> In order to most accurately calculate market shares 4 of LabCorp and Westcliff in the relevant product market, it is necessary to 5 aggregate sales data and other market share metrics from the competitors in the 6 7 relevant market, even small fringe competitors like Sun. Further, the FTC has relied on the documents and data it received from Sun to refute LabCorp's claim 8 that irrelevant fringe players like Sun are poised to replicate the competition that is 9 lost with the acquisition of Westcliff. Evidence from Sun also supports the FTC's 10 analysis of market definition, the likelihood and sufficiency of entry into the 11 relevant market, and potential anti-competitive effects of the acquisition in the 12

17 <sup>2</sup> Sun's assertion that it did not have a legal obligation to cooperate with the 18 FTC and that it provided information to the FTC voluntarily is incorrect. Pursuant to its investigative authority under 15 U.S.C. § 57b-1 and 16 C.F.R. § 2.7, the FTC 19 issued a issued a Civil Investigative Demand ("CID") to Sun on July 29, 2010. See 20 CID Issued to Sun Clinical Laboratories, July 29, 2010. Sun provided the documents for which it now seeks protection pursuant to this CID. See CID 21 Response from Sun Clinical Laboratories, Aug. 23, 2010. Similarly, 15 U.S.C. 22 § 49 provides the FTC with the authority to "require by subpoend the attendance and testimony of witnesses and the production of all such documentary evidence 23 relating to any matter under investigation." The FTC permitted Sun to submit a 24 declaration in lieu of testifying pursuant to an investigative subpoena in order to minimize the burden on Sun. See Declaration of Francis Sun (Oct. 29, 2010). The 25 FTC will submit the CID Issued to Sun Clinical Laboratories on July 29, 2010, the 26 CID Response from Sun Clinical Laboratories on Aug. 23, 2010, and the Declaration of Francis Sun in camera upon request of the Court. 27

28

13

15

<sup>14</sup> <sup>1</sup> Despite Sun's assertion to the contrary, LabCorp served Defendants' First Request for Documents to Plaintiff on December 17, 2010, which seeks, among other things, information and materials received from and communications with 16 third parties during the FTC's investigation.

relevant market and the FTC should be able, with appropriate protections, to use
 that information as evidence in this matter. Finally, the FTC's economic expert,

Dr. Frederick Flyer, has used information gained from Sun to calculate market shares.

## **CONCLUSION**

Because the existing Protective Order is sufficient to protect Sun's interests and because the Sun information is a necessary component of the evidence in this matter (and the underlying administrative trial), Plaintiff respectfully requests that the Court deny Nonparty Sun's Motion for an Additional Broader Protective Order.

A proposed order is attached.

Dated: January 18, 2011

Respectfully submitted,

By: \_/s/ Stephen A. Mohr\_\_

Stephen A. Mohr (Cal. Bar No. 246340)

Federal Trade Commission 600 Pennsylvania Ave., N.W. Washington, DC 20580 Tel: (202) 326-2850 Fax: (202) 326-2624 smohr@ftc.gov

## **DECLARATION OF SERVICE BY EMAIL**

I, the undersigned, declare:

 That declarant is and was, at all times herein mentioned, a citizen of the United States, over the age of 18 years, and not a party to or interested in the within action; that declarant's business address is 600 Pennsylvania Avenue N.W. Washington, D.C. 20001.
 That on January 18, 2011, declarant served the PLAINTIFF'S OPPOSITION TO NONPARTY SUN CLINICAL LABORATORIES' MOTION FOR AN ADDITIONAL BROADER PROTECTIVE ORDER by emailing a true and correct PDF to J. Robert Robertson at robby.robertson@hoganlovells.com, Corey Roush at corey.roush@hoganlovells.com, and to R. W. Chong at reobertchong@doochonglaw.com.

\_/s/ Stephen A. Mohr\_\_\_\_\_

Stephen A. Mohr Counsel for Plaintiff Federal Trade Commission